EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploratory Evaluation of Topical Tacrolimus for Prevention of Breast Cancer-Related Arm Lymphedema: A Multicenter Non-Randomized Pilot Study

Frederik Gulmark Hansen iD, Mads Gustaf Jørgensen iD, Kim Gordon iD, Christina Kjær, Lena Felicia Carstensen, Mette Tambour, Bibi Gram iD, Jørn Bo Thomsen iD, Jens Ahm Sørensen iD

Cancers · 24.11.2025 · 17 (23) · 3753

DOI: 10.3390/cancers17233753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.11.2025. Verfasst von Frederik Gulmark Hansen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit for Plastic Surgery, Odense University Hospital, 5000 Odense, Denmark. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, Novo Nordisk Foundation, Dagmar Marshall's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer-related lymphedema (BCRL) remains a challenging complication for breast cancer survivors. Currently, there are no effective pharmacological options available to address this condition. Emerging research highlights the critical role of inflammation, lymphatic dysfunction, and T-cell activity in the development of BCRL. Tacrolimus, a calcineurin inhibitor, has demonstrated promising results in preclinical studies for reducing inflammation, enhancing lymphatic function, and modulating T-cell activity—key mechanisms implicated in BCRL pathogenesis. This study investigates whether topical tacrolimus ointment can reduce the incidence and severity of BCRL, providing a novel approach to mitigate this debilitating condition.

Methods

A parallel, open-label non-randomized controlled multicenter clinical pilot trial was conducted from February 2020 to June 2022. Female participants undergoing axillary lymph node dissection (ALND) were recruited and divided into an intervention group (n = 22) receiving topical tacrolimus 0.1% ointment daily for 12 months and a control group (n = 39). Outcomes included lymphedema diagnosis (primary), arm volume, bioimpedance spectroscopy, quality of life (QOL) scores, and adverse events. Assessments were performed at baseline and at 3, 6, 9, and 12 months.

Results

At 12 months, lymphedema was diagnosed in 3 of 18 patients (16.7%) in the intervention group and 4 of 37 patients (10.8%) in the control group (p > 0.05). Mean increase in at-risk arm volume was 80.7 mL in the intervention group versus 116.1 mL in the control group (p > 0.05). Disease-specific quality of life scores worsened in both groups, but scores returned to baseline at 12 months in the intervention group only. Adverse events were mild and manageable, with no serious events reported.

Conclusions

While topical tacrolimus did not significantly reduce the incidence of lymphedema, exploratory patterns in symptom onset and quality-of-life measures indicate that further investigation in larger randomized trials may be warranted.

Schlagwörter

Stichwörter der Autor:innen

breast cancerlate effectslymphedemaquality of lifetacrolimustopical therapy

Autor:innen und Institutionen

  • Research Unit for Plastic Surgery, Odense University Hospital, 5000 Odense, Denmark.
  • Institute of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.
  • Department of Physio- and Occupational Therapy, Lillebelt Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, 5000 Odense, Denmark.
  • Department of Plastic and Breast Surgery, Lillebaelt Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.
  • Department of Physiotherapy and Occupational Therapy, University Hospital of Southern Denmark, 6700 Esbjerg, Denmark.

ORCID-Profile: Frederik Gulmark Hansen, Mads Gustaf Jørgensen, Kim Gordon, Bibi Gram, Jørn Bo Thomsen, Jens Ahm Sørensen

Förderung

  • Danish Cancer Society
  • Novo Nordisk Foundation
  • Dagmar Marshall's Foundation
  • Fonden af 1870
  • Guldsmed A. L. Rasmussen's Memorial Fund
  • Grosserer A. V. Lykfeldt and Wife's legacy foundation
  • Dagmar Marshall’s Foundation
  • Fonden af 1870, Guldsmed A. L. Rasmussen’s Memorial Fund

Zitieren

APA

Gulmark Hansen, F., Jørgensen, M. G., Gordon, K., Kjær, C., Carstensen, L. F., Tambour, M., Gram, B., Thomsen, J. B., & Sørensen, J. A. (2025). Exploratory Evaluation of Topical Tacrolimus for Prevention of Breast Cancer-Related Arm Lymphedema: A Multicenter Non-Randomized Pilot Study. Cancers, 17(23), 3753. https://doi.org/10.3390/cancers17233753

Vancouver

Gulmark Hansen F, Jørgensen MG, Gordon K, Kjær C, Carstensen LF, Tambour M, et al. Exploratory Evaluation of Topical Tacrolimus for Prevention of Breast Cancer-Related Arm Lymphedema: A Multicenter Non-Randomized Pilot Study. Cancers. 2025;17(23):3753. doi:10.3390/cancers17233753

BibTeX
@article{GulmarkHansen2025,
  author = {Gulmark Hansen, Frederik and Jørgensen, Mads Gustaf and Gordon, Kim and Kjær, Christina and Carstensen, Lena Felicia and Tambour, Mette and Gram, Bibi and Thomsen, Jørn Bo and Sørensen, Jens Ahm},
  title = {Exploratory Evaluation of Topical Tacrolimus for Prevention of Breast Cancer-Related Arm Lymphedema: A Multicenter Non-Randomized Pilot Study},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {23},
  pages = {3753},
  doi = {10.3390/cancers17233753}
}
Kostenlos starten →